Video

The Future of AI in Drug Discovery: How Artificial Intelligence is Generating Ideas for New Medicines

In this latest podcast episode from The Future Labs, Dr Jackie Hunter, our Board Director at BenevolentAI, explores how artificial intelligence is generating new ideas for new medicines, and cutting the time and cost of designing drugs to bring them to patients faster.

The development of new drugs and treatments is an extremely complicated and failure-prone process. As an example of the scale of the challenge - developing a drug and getting it to market can take 10-15 years and cost more than $2.5 billion. What’s more, the top selling drugs available today only work for 30-50% of the patients to whom they are prescribed.

Although technology has been an indispensable component of drug discovery for decades, patients are not yet authentically benefiting from its potential at it relates to the generation of  new and more effective treatments.

In this podcast, Jackie discuss how the high cost and decline in tangible outputs from drug R&D, has resulted in the need to seek out new inventive solutions to improve the efficiency of medicinal development. We explore a radically different approach - how building machine learning tools and applying artificial intelligence to drug discovery can create new ideas to be interpreted by scientists in the lab.

Listen to Jackie explain BenevolentAI’s approach to drug discovery and the progress we are making to better understand diseases and to develop treatments for the millions of patients that need them.

More Posts

You Might Also Like

News
BenevolentAI Announces Board Changes
BenevolentAI today announces the appointment of Dr. Susan Liautaud as a member of the board of directors of the Company with effect from 30 June 2022. Dr. Susan Liautaud will act as Independent Non-Executive Director of the Company.
May 25, 2022
News
BenevolentAI achieves third milestone in its AI-enabled drug discovery collaboration with AstraZeneca
AstraZeneca selects another novel target for idiopathic pulmonary fibrosis from the collaboration for its drug development portfolio.
May 17, 2022
Blog
FDA converts emergency approval of baricitinib — first identified as a COVID treatment by BenevolentAI — to a full approval
The FDA has converted its emergency approval of baricitinib to a full approval, underscoring the strength of BenevolentAI’s AI-derived hypothesis.
May 12, 2022
News
BenevolentAI Begins Trading On Euronext Amsterdam
BenevolentAI, a leading, clinical-stage AI-enabled drug discovery company, announces that trading in its shares is expected to begin today, following completion of its business combination with Odyssey Acquisition S.A. on 22 April 2022.
Apr 25, 2022
Video
BenevolentAI · AI-Enabled Drug Discovery
Advanced technologies, combined with an exponential increase in biomedical data and research, provide an unparalleled opportunity to unravel the mysteries of diseases that have gone untreated for too long.
Apr 25, 2022
News
BenevolentAI joins the World Economic Forum’s Global Innovators Community
BenevolentAI joins the World Economic Forum’s Global Innovators Community to help ethically deploy AI to create a more sustainable, inclusive and resilient world.
Apr 21, 2022